Paper Details

  1. Home
  2. Paper Details

Bexarotene ligand pharmaceuticals.

Author: HurstR E

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Bexarotene, a retinoid X receptor (RXR)-selective antitumor retinoid, is approved for the treatment of cutaneous T-cell lymphoma (CTCL). Both oral capsules and topical gel formulations are available. The drug has shown promising efficacy and a manageable side effect profile.
Paper Details　
Original Abstract of the Article :
Bexarotene (LGD-1069), from Ligand, was the first retinoid X receptor (RXR)-selective, antitumor retinoid to enter clinical trials. The company launched the drug for the treatment of cutaneous T-cell lymphoma (CTCL), as Targretin capsules, in the US in January 2000 [359023]. The company filed an NDA...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/11249708

データ提供：米国国立医学図書館（NLM）

Bexarotene ligand pharmaceuticals

This research explores the exciting field of [pharmaceutical development and cancer therapy], focusing on the development and clinical application of bexarotene, a selective retinoid X receptor (RXR) agonist, in the treatment of cutaneous T-cell lymphoma (CTCL). The authors highlight the journey of bexarotene from initial clinical trials to FDA approval and subsequent market launch. They delve into the drug's mechanism of action, its efficacy in treating various stages of CTCL, and its safety profile. The research emphasizes the crucial role of bexarotene as a therapeutic option for patients with this challenging type of lymphoma.

Bexarotene: A Beacon of Hope for CTCL Patients

The research showcases the remarkable progress made in developing bexarotene as a targeted therapy for CTCL. This drug's selective RXR activation, coupled with its demonstrated efficacy in treating different stages of CTCL, positions it as a valuable treatment option for patients facing this challenging form of lymphoma. The journey from clinical trials to FDA approval is a testament to the dedication of researchers and clinicians in seeking innovative therapies for difficult-to-treat cancers.

Targeted Therapy: A Precision Approach to Cancer

The success of bexarotene in treating CTCL highlights the promise of targeted therapy in cancer treatment. By selectively targeting specific molecular pathways involved in cancer development, these therapies offer a more precise and potentially less toxic approach compared to traditional chemotherapy. This research encourages continued exploration into targeted therapies, opening doors to new and effective treatments for a wider range of cancers.

Dr.Camel's Conclusion

This research is like a caravan crossing a vast desert, carrying the hope of effective treatment for CTCL patients. The development and approval of bexarotene represents a significant milestone in the fight against this challenging form of lymphoma. It's a testament to the power of targeted therapy and the relentless pursuit of innovative treatments for cancers that once seemed insurmountable.
Date :
  1. Date Completed 2001-04-19
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

11249708

DOI: Digital Object Identifier

11249708

Related Literature

Article Analysis
・Effects of bexarotene topical
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.